Professor Andrew Herx-heimer, emeritus fellow at the UK Cochrane Centre, told the British Medical Journal that changes to the British drug industry's voluntary code of practice [3] were minimal. "This is very competent window dressing but not much has changed at all," he said. The drug industry [4]'s revised code followed the House of Commons health select committee's report, The Influence of the Pharmaceutical Industry [5], which found numerous flaws in the system of self-regulation. While the new code introduces new restrictions aimed at limiting the extent of drug company hospitality - including luxury accommodation and first class flights - doctors have criticized the limited sanctions for breaches. "The key weakness is that this is regulated by the industry, and so it is written in such a way that it doesn't seriously inconvenience companies if anything goes wrong," said Ike Iheanacho, the editor of the Drugs and Therapeutics Bulletin.